The UN’s health agency endorsed a second malaria vaccine for children, aiming to significantly reduce mortality from the disease. Annually, nearly half a million African children perish due to malaria, a mosquito-borne parasitic affliction.
The newly approved R21/Matrix-M vaccine, created by Oxford University and the Serum Institute of India, joins the RTS,S vaccine, becoming a crucial tool in combating the widespread disease.
While initially available in select African countries, broader availability is expected by mid-2024, with both vaccines demonstrating around 75% efficacy. The R21/Matrix-M vaccine not only bridges a supply-demand gap but also paves the way towards a more malaria-resilient future.
Additionally, new vaccines for dengue and meningitis have been recommended by the WHO, expanding the protective arsenal against prevalent diseases.
